These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25567681)

  • 21. The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens.
    Jin S; Kim MH; Park JH; Jung HJ; Lee HJ; Kim SW; Lee JM; Kim S; Chang HH
    Infect Chemother; 2015 Dec; 47(4):239-46. PubMed ID: 26788407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
    Bonjoch A; Puig J; Pérez-Alvarez N; Juega J; Echeverría P; Clotet B; Romero R; Bonet J; Negredo E
    Medicine (Baltimore); 2016 Aug; 95(32):e4507. PubMed ID: 27512868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort.
    Monteiro N; Branco M; Peres S; Borges F; Mansinho K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19565. PubMed ID: 25394072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
    Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
    Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
    J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing chronic kidney disease in the older adults living with HIV.
    Post FA
    Curr Opin Infect Dis; 2017 Feb; 30(1):4-11. PubMed ID: 27828808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
    Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
    J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
    Tanaka H; Arai M; Tomoda Y; Wada T; Yago K; Satoh M
    J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
    Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I
    Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine.
    Casado JL; Monsalvo M; Vizcarra P; Fontecha M; Serrano-Villar S; Moreno S
    HIV Med; 2019 Nov; 20(10):648-656. PubMed ID: 31321875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
    Ryom L; Mocroft A; Kirk O; Worm SW; Kamara DA; Reiss P; Ross M; Fux CA; Morlat P; Moranne O; Smith C; Lundgren JD;
    J Infect Dis; 2013 May; 207(9):1359-69. PubMed ID: 23382571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
    Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
    Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
    Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
    Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.